This CRISPR/Cas9-edited polyclonal KLRB1 knockout product comprises a heterogeneous HeLa cell population with targeted disruption of the KLRB1 gene. The polyclonal format provides a robust loss-of-function model that preserves the genetic diversity arising from independent editing events, enabling studies of CD161-dependent phenotypes in a cervical adenocarcinoma background. As a population-level knockout, it is suitable for experiments where clonal variation is not required, and it avoids the biases associated with single-cell-derived clones. The cells are delivered as a ready-to-use frozen stock, facilitating integration into routine cell culture workflows for immunology and oncology research.
The parental HeLa cell line is a widely characterized human epithelial model originally derived from cervical adenocarcinoma tissue in 1951. These cells are HPV18-positive and have been employed extensively to investigate viral oncogenesis, epithelial biology, and cellular signaling pathways. The HeLa background provides a relevant context for exploring KLRB1 function in cervical cancer, particularly given the established link between HPV-driven malignancies and immune evasion mechanisms. The immortalized nature of HeLa cells ensures reproducible growth and experimental scalability, while their epithelial origin supports studies of innate and adaptive immune interface in solid tumors.
KLRB1 encodes CD161 (NKR-P1A), a type II transmembrane C-type lectin receptor that functions as an inhibitory immunoreceptor. Upon engagement by its cognate ligand LLT1 (CLEC2D), CD161 recruits the phosphatases SHP-1 and SHP-2, leading to dephosphorylation of proximal signaling molecules such as LCK and ZAP70, and subsequent attenuation of T cell receptor and natural killer cell activation pathways. This signaling cascade is regulated by cytokines including IL-12, IL-15, and IL-18, and transcriptional regulators T-bet and EOMES. Downstream impacts include reduced secretion of IFN-??, TNF-??, and granzyme B, linking CD161 directly to effector function modulation. The CD161?CLLT1 axis thereby serves as a checkpoint that fine-tunes immune cell cytotoxicity and cytokine responses.
In the HeLa cervical cancer model, CD161 expression may contribute to immune escape by dampening local immune surveillance. Knockout of KLRB1 disrupts this inhibitory circuit, allowing researchers to dissect how tumor-intrinsic or microenvironmental CD161?CLLT1 interactions influence antitumor immunity. Given the HPV-positive status of HeLa cells, the knockout model offers a platform to examine how viral oncoproteins intersect with immunoregulatory receptors. The polyclonal nature ensures that residual populations can be studied without confounding clonal artifacts, making it particularly suited for long-term functional assays and drug response studies in immune co?culture settings.
Typical applications include validation of CD161 as an immunotherapy target, mechanistic studies of C-type lectin receptor signaling, and genome-wide CRISPR screens focused on immune evasion. Standard assays employ Western blotting and flow cytometry to confirm loss of CD161 protein, RT?qPCR for KLRB1 transcript assessment, and co?immunoprecipitation to probe CD161?CLLT1 binding. Functional readouts include cytokine secretion ELISA for IFN??? and TNF???, immune co?culture killing assays, and transcriptomic profiling via RNA?seq. These tools enable detailed exploration of how CD161 regulates cervical cancer cell interactions with natural killer and T cells. For further information, please contact Ascent Research.
